Investing.com -- GeneDx Holdings Corp (NASDAQ: WGS) stock surged 18.5% after the American Academy of Pediatrics (AAP) issued updated guidance recommending exome and genome sequencing as first-tier ...

Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk ...

GeneDx Holdings Corp. leverages genomics leadership with robust growth, despite recent stock challenges. Click for more on ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf ...

CVS, BrightSpring, and GeneDx are tapping into AI, staffing trends, and precision medicine to drive future healthcare gains.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of ...

The Medical Services sector is experiencing significant transformation fueled by advancements in technology, increased ...

NEWTOWN, Pa., June 13, 2025 /PRNewswire/ — Edelson Lechtzin LLP is investigating potential violations of the federal ...

The journey doesn’t end with a diagnosis. AI is helping patients move faster toward new treatments, clinical trials, and ...

The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of $1.09 per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction.

Genedx Holdings Corp is listed on the CBOE trading with ticker code WGS.US. It has a market capitalisation of $1.83b, with approximately 28.53m shares in issue. Over the last year, Genedx Holdings ...